CeriBell (CBLL) Q2 2026 Earnings Call Transcript

Ceribell reported Q2 revenue of $28.1M, up 33% YoY (vs. $21.2M a year ago), and raised full-year 2026 guidance to $114M–$117M from $112M–$116M (+28% to +31% YoY). Gross margin hit a record 92% (89% ex-$1.6M tariff refund), while net loss narrowed to $19.3M ($0.51/share) from $13.6M ($0.38/share) a year ago despite higher OpEx (+37% YoY). The company also secured CMS NTAP reimbursement effective Oct. 1, 2026 (up to $2,170 incremental per qualified patient) and received FDA 510(k) clearances for new delirium algorithms plus additional hardware clearances, with a credit facility refinanced for up to $60M committed capital extending repayment to 2031.

Analysis

The setup is less about a one-quarter beat and more about proving that the installed base can compound without proportionate sales friction. The clearest mechanism is operating leverage hiding underneath the headline: if gross margin really sits in the high-80s absent one-offs, then incremental uptake from existing hospitals should convert efficiently once litigation noise fades and newer reps age into productivity. That makes the business look closer to a consumables-plus-software model than a one-time device sale, which usually deserves a richer multiple if retention and repeat use hold.

The bigger second-order effect is on the hospital ROI equation. NTAP plus algorithm-driven workflow simplification lowers the hurdle for ICU adoption, which should help Ceribell convert decision-makers who previously viewed EEG as too cumbersome or too specialist-dependent. That creates pressure on legacy EEG workflows and adjacent acute-care monitoring vendors: once a hospital standardizes on a simpler brain-monitoring platform, the switching costs become clinical, not just procurement-based.

Near term, the risk is that the market extrapolates 2027 before the launch sequence is de-risked. The next 1-3 months matter for evidence of sustained same-store acceleration and whether delirium converts from pilot interest into reimbursable, repeatable utilization; if that stalls, the multiple can compress quickly because the current narrative already prices in optionality. Over 6-18 months, the key falsifier is any sign that account adds revert once the easiest cohort matures or that the new hardware remains a feature story rather than a revenue driver.

Key Decisions for Investors

• Buy CBLL on any post-earnings pullback; use a 3-6 month horizon and size for volatility. Thesis is that the market is underappreciating installed-base monetization and the margin bridge from tariffs/litigation normalization.
• If liquidity allows, express the view with CBLL Jan-2027 call spreads rather than outright stock. Risk/reward is better if the stock is rerated on 2027 optionality before hardware/reimbursement contribution is modeled in.
• Watch for a confirmation trade: add to CBLL only if Q3 shows sequential same-store growth improvement and early delirium reimbursement claims are being accepted. Failure here would be the first clean thesis break.
• Pair trade idea: long CBLL vs a broad medtech/healthcare equipment proxy such as IHI on the view that CBLL has a clearer near-term revenue re-acceleration path while the basket is more exposed to mature, lower-growth names.
• Set a falsifier: if gross margin falls back below the high-80s ex-one-offs or active account adds decelerate meaningfully over the next two quarters, reduce exposure; that would imply the growth engine is less repeatable than management suggests.